4DMedical Limited (4DX)
Market Closed
ASX ASX Primary 871.06M Market Cap
- P/E Ratio
- Div Yield
5,075,903 Volume
- Eps
Want to track 4DX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 74 days
Summary
4DX closed today higher, an increase of 3.18% from yesterday's close, completing a monthly increase of 68.79%. Over the past 12 months, 4DX stock gained 502.06%.
4DX is not paying dividends to its shareholders.
The last earnings report, released on Dec 03, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports. The next scheduled earnings report is due on Mar 02, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on ASX (AUD).
4DMedical Limited (4DX) FAQ
On which exchange is it traded?
4DMedical Limited is listed on ASX.
What is its stock symbol?
The ticker symbol is 4DX.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 871.06M.
When is the next earnings date?
The next earnings report will release on Mar 02, 2026.
Has 4DMedical Limited ever had a stock split?
No, there has never been a stock split.
4DMedical Limited Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Dr. Andreas Fouras M.A.I.C.D., Ph.D. CEO | ASX Exchange | AU0000095416 ISIN |
| AU Country | 145 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
4DMedical Limited is a pioneering medical technology company based in Carlton, Australia, with operations extending to the United States. Founded in 2012, the company is at the forefront of advancing medical research technology by developing non-invasive, four-dimensional imaging solutions for respiratory health. Its mission revolves around enhancing patient care and outcomes through innovative imaging technologies that provide comprehensive insights into lung function and health.
Products and Services
- X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS): This groundbreaking software utilizes X-rays to generate detailed images of lung airflow, offering unprecedented insights into lung health. Ideal for diagnostic and monitoring purposes, XV LVAS enables healthcare providers to visualize and assess lung function non-invasively, facilitating more informed decision-making in patient care.
- Computed Tomography Lung Ventilation Analysis Software (CT LVAS): Operating on computed tomography (CT) scans, this image processing software provides functional details of lung health. CT LVAS enhances the diagnostic capabilities of CT scans by adding a functional analysis of lung ventilation, thereby offering a more comprehensive understanding of various lung conditions.
- XV Scanner: The XV Scanner is a specialized lung function scanner developed by 4DMedical. Designed to be used in conjunction with the XV LVAS software, this device further enhances the capability to assess and analyze lung ventilation and function, supporting the early detection and management of respiratory diseases.
- Permetium: Permetium represents a significant advancement in pulmonary imaging technology. As a multi-function imaging system, it is engineered for a broad range of pulmonary investigations, offering versatile applications in respiratory diagnostics and research. Through its innovative design, Permetium sets new standards in the visualization and analysis of lung function, aiding in the precise diagnosis and treatment of pulmonary disorders.
Contact Information
Address: Melbourne Connect, Carlton, VIC, Australia, 3053
Phone: 61 3 9545 5940
Website: https://4dmedical.com
